Related Experiment Videos
Acetyltransferases and tumour suppression
1Regulation of Cell Growth Laboratory, NCI-FCRDC, Frederick, Maryland 21702-1201, USA. phillips@ncifcrf.gov
Abstract:
The acetyltransferase p300 was first identified associated with the adenoviral transforming protein E1A, suggesting a potential role for p300 in the regulation of cell proliferation. Direct evidence demonstrating a role for p300 in human tumours was lacking until the recently publication by Gayther et al, which strongly supports a role for p300 as a tumour suppressor. The authors identify truncating mutations associated with the loss or mutation of the second allele in both tumour samples and cell lines, suggesting that loss of p300 may play a role in the development of a subset of human cancers.
Insights
The acetyltransferase p300 (also known as EP300) may function as a tumor suppressor. Recent research found mutations in p300 in human cancers, suggesting its loss contributes to tumor development.
Area of Science:
- Molecular Biology
- Oncology
- Virology
Background:
- The acetyltransferase p300 was initially identified in association with the adenoviral transforming protein E1A.
- This association suggested a potential role for p300 in regulating cell proliferation.
Purpose of the Study:
- To investigate the role of p300 in human tumors.
- To provide direct evidence for p300's function in cancer development.
Main Methods:
- Analysis of tumor samples and cell lines for mutations in the p300 gene.
- Identification of truncating mutations and loss or mutation of the second allele.
Main Results:
- Direct evidence supporting a tumor suppressor role for p300 in human cancers was established.
- Truncating mutations and loss of heterozygosity in p300 were identified in tumor samples and cell lines.
Conclusions:
- Loss or mutation of p300 is implicated in the development of a subset of human cancers.
- p300 functions as a tumor suppressor, and its alteration contributes to oncogenesis.